Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Identification of SK3 channel as a new mediator of breast cancer cell migration

Marie Potier, Virginie Joulin, Sébastien Roger, Pierre Besson, Marie-Lise Jourdan, Jean-Yves LeGuennec, Philippe Bougnoux and Christophe Vandier
Marie Potier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginie Joulin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sébastien Roger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Besson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Lise Jourdan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Yves LeGuennec
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Bougnoux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Vandier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-06-0194 Published November 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Involvement of SK channels in MDA-MB-435s cell migration. Effect of apamin (A), Lei-Dab7, TEA, 4-AP (B), and increasing concentration of external K+ (C) on cell migration. Cells were seeded at 40,000 in a cell culture insert in DMEM with 5% fetal bovine serum ± drugs or [K+] 60 mmol/L. The lower compartment of the insert contained DMEM with 10% fetal bovine serum as a chemoattractant ± drugs or [K+] 60 mmol/L. After 24 h, cells of the lower compartment were stained with hematoxylin (A, bottom) and counted. The normalized cell number corresponded to the ratio of total number of migrating cells in presence of drug or [K+] 60 mmol/L/total number of migrating cells in control experiments. The drug concentrations selected have no effect on cell proliferation and viability (example with apamin in A, inset). Bar, 10 μm for the two panels. From two separate experiments done in triplicate. Columns, mean; bars, SE. *, P < 0.05, significantly different from control.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Regulation of resting membrane potential by SK channels in MDA-MB-435s cells. A, example of whole-cell macroscopic K+ currents recorded in one cell without (control) or with apamin in the external medium. Currents were generated by stepwise 8-mV depolarizing pulses (400-ms duration; 5-sec intervals) from a constant holding potential of −70 mV up to +58 mV. Signals were filtered at 1 kHz and digitized at 10 kHz. B and C, current density was obtained by dividing the averaged steady-state current elicited at +26 mV (recorded during the latest 50 ms of the pulse) by the respective cell capacitance. Membrane capacitance was calculated by integrating the capacitive current measured during a 10-mV voltage step. Columns, mean of the inhibitory effects of apamin (n = 4), TEA (n = 7), 4-AP (n = 8), and TEA plus 4-AP (n = 3); bars, SE. D, variations of membrane potential recorded in control conditions (physiologic saline solution without drugs, n = 11) and in presence of TEA (n = 7), 4-AP (n = 8), and TEA plus 4-AP (n = 3). Membrane potential was measured in current-clamp mode (I = 0) just after the disruption of the patch membrane. Columns, mean; bars, SE *, P < 0.05, significantly different from control.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    SK3 protein is expressed in MDA-MB-435s and in tumor breast tissue. A, detection of SK channels (SK1, SK2, SK3, and SK4) and of the housekeeping ribosomal S14 mRNA in MDA-MB-435s. Reverse transcription-PCR was done in MDA-MB-435s cells and in human central nervous system cDNA as a positive control. Primers used for the reverse transcription-PCR experiments are listed in Materials and Methods. Representative examples of three separate experiments. B, representative Western blot pattern of SK2 and SK3 protein expression in cancerous and noncancerous mammary epithelial cell lines. Lysates of human mammary cancer cell lines (MDA-MB-435s, MDA-MB-231, MCF-7, T47D, and SKBR3), of noncancerous mammary epithelial cell lines (184A1, MCF-10A), and of rat hippocampus tissue (used as positive control) were prepared in lysis buffer (SDS 5%, protease inhibitors 1%, phenylmethylsulfonyl fluoride 200 mmol/L). Cell extracts were subjected to electrophoresis on SDS-polyacrylamide gel under reducing conditions and the signal was detected by enhanced chemiluminescence. Results were provided in triplicate. The numbers represent the SK2 and SK3 band absorbance normalized to those obtained with actin. C, confocal pictures showing the cellular location of SK3 channel in MDA-MB-435s cells. Cells were fixed and permeabilized with 100% methanol before antibody staining. D, Western blot pattern showing the expression of SK2 and SK3 proteins in tumor (n = 4) and nontumor (n = 4) breast biopsies. The numbers represent the SK2 and SK3 band absorbance normalized to those obtained with actin.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    SK3 gene transcript destruction decreases migration of MDA-MB-435s cells, and SK3 gene expression increases migration of 184A1 cells. A, top, Western blot patterns showing the silencing effect on the expression of SK3 protein of two siRNAs designed against SK3 mRNA. Cells were transfected with siRNA-LipofectAMINE complexes for 24, 48, and 72 h. A scrambled siRNA was used as negative control. siRNA oligonucleotide sequences are listed in Materials and Methods. Bottom, histograms showing the inhibitory effect on MDA-MB-4345s cell migration after 24, 48, and 72 h of siRNA transfection with or without 10 nmol/L apamin. Results from two separate experiments done in triplicate. Columns, mean; bars, SE. Normalization of cell number done as described in Fig. 1. Note that the cells have lost their sensitivity for apamin after siRNA transfection, indicating a specific effect on SK3 protein. B, top, Western blot patterns showing the expression of the SK3 protein channel after transient transfection of SK3-pTracer-CMV2 plasmid (SK3 transfection) or empty vector (control transfection) in cancerous (MCF-7) and noncancerous (184A1) mammary epithelial cell lines. Bottom, histograms showing the number of migrating cells after transient transfection, with or without 10 nmol/L apamin. Results from two separate experiments done in triplicate. Columns, mean; bars, SE Note that SK3-transfected cells have gained a sensitivity to apamin, indicating a specific expression of SK3 channel.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Proposed model to explain how SK3 channel promotes epithelial cell migration. Top, when SK3 channel is not present, plasma membrane is depolarized (−30 to −20 mV) and Ca2+ influx through voltage-independent Ca2+ channels is low. As a consequence, intracellular Ca2+ concentration is low and epithelial cell have a low migration capacity. Bottom, expression of SK3 leading to SK3 channel activity would result in an increase of K+ efflux. This leads to a shift of membrane potential of epithelial cells to more negative values (hyperpolarization to −50 mV), which is equivalent to a stronger electrochemical driving force supporting Ca2+ entry through voltage-independent Ca2+ channels. This Ca2+ entry would increase intracellular Ca2+ concentration that promotes epithelial cell migration. Like a positive feedback loop, Ca2+ entry would also increase the activity of SK3 channel, leading to a more negative membrane potential.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 5 (11)
November 2006
Volume 5, Issue 11
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of SK3 channel as a new mediator of breast cancer cell migration
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Identification of SK3 channel as a new mediator of breast cancer cell migration
Marie Potier, Virginie Joulin, Sébastien Roger, Pierre Besson, Marie-Lise Jourdan, Jean-Yves LeGuennec, Philippe Bougnoux and Christophe Vandier
Mol Cancer Ther November 1 2006 (5) (11) 2946-2953; DOI: 10.1158/1535-7163.MCT-06-0194

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Identification of SK3 channel as a new mediator of breast cancer cell migration
Marie Potier, Virginie Joulin, Sébastien Roger, Pierre Besson, Marie-Lise Jourdan, Jean-Yves LeGuennec, Philippe Bougnoux and Christophe Vandier
Mol Cancer Ther November 1 2006 (5) (11) 2946-2953; DOI: 10.1158/1535-7163.MCT-06-0194
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
  • Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
  • Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement